论文部分内容阅读
美国癌症联合委员会(AJCC)癌症分期系统是目前应用最广泛的肿瘤分期系统,已成为指导恶性肿瘤诊治及判断预后的重要参考。近期发布的AJCC第8版胰腺癌分期系统在T分期和N分期上进行了较大的修订。最新循证医学证据显示,肿瘤大小和病人的生存关系更为密切,AJCC第8版T分期T1-T3根据肿瘤大小界定,不再使用肿瘤胰腺外侵犯的概念;T4是指肿瘤侵犯腹腔干动脉、肠系膜上动脉和(或)肝总动脉,摒弃可切除性的定义。原N1分期则根据转移淋巴结数目分层为N1和N2。AJCC第8版胰腺癌分期系统相较第7版,分期更细,与预后的相关性更大;定义更为清晰,判断标准更突出客观性的可测量指标,摒除了主观性的指标。
The American Cancer Joint Committee (AJCC) is the most widely used cancer staging system and has become an important reference for guiding the diagnosis and treatment of malignant tumors and prognosis. The recently released AJCC version 8 pancreatic cancer staging system has been greatly revised in both T stage and N stage. The latest evidence-based medical evidence shows that the size of the tumor is more closely related to the survival of the patient. The T stage of AJCC 8th edition, T1-T3, is defined by the size of the tumor and no longer uses the notion of external invasion of the pancreatic pancreas. T4 refers to the invasion of the celiac trunk by the tumor , The superior mesenteric artery and / or the common hepatic artery, abandoning the definition of resectability. The original N1 staging is based on the number of metastatic lymph nodes stratified into N1 and N2. Compared with the seventh edition of the AJCC Eighth Edition pancreatic cancer staging system, the staging system is more detailed and more relevant to the prognosis; the definition is clearer and the judgment criteria are more objective and measurable indicators, excluding the subjective indicators.